Business
Tetra Bio-Pharma Announces Clinical Advancements and Establishment of At-the-Market Equity Program
Tetra Bio-Pharma Announces Clinical Advancements and Establishment of At-the-Market Equity Program.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\n\n\n\nTetra Bio-Pharma Announces Clinical Advancements and Establishment of At-the-Market Equity Program\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nTetra Bio-Pharma Announces Clinical Advancements and Establishment of At-the-Market Equity Program\nCanada NewsWire\nOTTAWA, ON, May 28, 2021\n\n\n\nFirst REBORN1© patient enters clinical trial. Positive results of first study in Sars-CoV-2 infected mice. Filing of IND for ARDS-003 Adaptive Phase 1a/1b clinical trial./NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/\n OTTAWA, ON, May 28, 2021 /CNW/ - Tetra Bio-Pharma Inc. (\"Tetra\" or the \"Company\") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development is pleased to announce that the first patient has entered the REBORN1© clinical trial; the first study of mice infected with Sars-CoV-2 virus demonstrates ARDS-003's potential to reduce clinical signs of infection; and that the Company is in the process of filing an Investigational New Drug application with the U.S. Food and Drug Administration (FDA) for ARDS-003.\nREBORN1©\nThe REBORN1© trial is designed to evaluate the effect of the Company's inhaled proprietary drug formulation, QIXLEEF™, against immediate release oral morphine sulfate on onset of pain relief in people living with cancer. QIXLEEF™ is a botanical drug product with a \"fixed ratio\" of THC and CBD and is inhaled through a Class 2 medical device vaporizer.\nDr. Hassman and the clinical staff have been trained on the study procedures and received the green light to start enrolling patients following the Site Initiation Visit. Patient enrolment is a multistep process that can last up to two weeks to determine the eligibility of the patient and leads to random allocation of the patient to either the comparator (immediate release morphine) or QIXLEEF™ arm of the cross-over designed trial. \nAccording to medical expert and Principal Investigator Dr. David Hassman \"We are excited...